Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Tolga Tanguler, EVP & Chief Commercial Officer of Alnylam Pharmaceuticals (ALNY), reported changes in beneficial ownership related to a performance-based award and subsequent sell-to-cover transactions. On 08/15/2025 Tanguler received 2,851 shares that vested from a performance-based stock unit granted on 03/01/2024 after achievement of a clinical milestone. Following the vesting, a series of automatic sales executed on 08/18/2025 sold varying blocks of shares to satisfy statutory tax withholding, with weighted-average sale prices reported in ranges from $447.53 up to $456.00 per share. After these transactions Tanguler beneficially owned 29,466 shares.
Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals (ALNY), received and sold shares following the vesting of performance-based stock units. A PSU tranche vested on 08/15/2025 after the Compensation Committee determined a clinical milestone was achieved, resulting in the issuance of 4,644 shares to Mr. Poulton. Between 08/18/2025 the reporting person had multiple automatic sales of shares to satisfy mandatory tax-withholding obligations at weighted-average prices in the $447.53–$456.00 range. The filing also notes 57 shares held indirectly via a managed account from the company 401(k) match.
Yvonne Greenstreet, Director and CEO of Alnylam Pharmaceuticals (ALNY), reported a mix of equity activity tied to performance compensation and tax withholding on vested awards. On 08/15/2025 she received 14,252 shares upon vesting of 30% of a performance-based stock unit awarded 03/01/2024 after a clinical milestone determination. Following that vesting, multiple automatic sales occurred on 08/18/2025 to satisfy mandatory sell-to-cover tax withholding, reducing her direct holdings from 63,200 to 56,221 shares. The filing also shows 407 shares held indirectly via a managed account and shares acquired under the company 401(k) matching program.
Kevin J. Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals (ALNY), reported insider transactions tied to vested performance-based awards. On 08/15/2025 he was issued 2,851 shares following vesting of 30% of a performance-based stock unit granted 03/01/2024 after a clinical milestone determination. On 08/18/2025 he sold a total of 1,396 shares via multiple transactions under a mandatory sell-to-cover provision to satisfy tax withholding, at weighted sale prices ranging roughly between $447.53 and $456.00 per share. Following these transactions he beneficially owned 23,515 shares directly and an additional 537 shares indirectly through a managed account.
Michael W. Bonney, a director of Alnylam Pharmaceuticals (ALNY), reported transactions on 08/18/2025 under a Rule 10b5-1 trading plan. On that date he acquired 11,250 shares of ALNY common stock at a reported price of $70.20 and sold 11,250 shares at a reported price of $450.00, both transactions recorded under the same date. Following the reported transactions his direct beneficial ownership is listed as 16,804 shares, and he also has 4,000 shares held indirectly by the Michael W. Bonney Revocable Trust. The filing notes the 10b5-1 plan was adopted on November 12, 2024, and that the related stock option was fully vested as of June 3, 2017.
Alnylam Pharmaceuticals (ALNY) filed a Form 144 reporting a proposed sale of 1,455 shares of common stock through UBS Financial Services on 08/19/2025. The filing lists an aggregate market value of $664,935.00 and shows 131,079,015 shares outstanding. The securities were acquired from the issuer as PSU on 08/15/2025 with payment recorded on the same date.
The filer certifies they are not aware of undisclosed material adverse information and discloses no sales of the issuer's securities in the past three months. The filing provides broker details and the exchange (NASDAQ) where the sale is expected to occur.
Alnylam Pharmaceuticals (ALNY) Form 144 summary: This notice reports the proposed sale of 11,250 shares of common stock acquired and to be sold on 08/18/2025. The shares were acquired the same day by exercise of stock options from the issuer and paid in cash. The broker listed is UBS Financial Services, Inc., 11 Madison Avenue, New York. The aggregate market value of the shares at the time of this filing is reported as $5,062,500.00. The filing states the issuer has 131,079,015 shares outstanding and names NASDAQ as the exchange. The filer reports "Nothing to Report" for securities sold by the person in the past three months. The filer also certifies they are not aware of undisclosed material adverse information.
Dennis A. Ausiello, a director of Alnylam Pharmaceuticals, executed multiple equity transactions on 08/14/2025 under a Rule 10b5-1(c) trading plan adopted May 15, 2025. The Form 4 reports exercises of stock options (codes M(1)) for option blocks of 9,000; 5,153; 4,581; 5,228; 4,032; and 3,454 shares at exercise prices ranging from $72.01 to $189.87 per share, each creating corresponding shares of common stock. The filing also shows open-market sales (codes S(1)) of multiple share blocks at weighted-average prices reported in ranges between $430.39 and $443.10 per share. After the reported transactions, the reporting person’s beneficial ownership counts are shown on individual lines (for example, 9,911; 15,064; 19,645; 24,873; 28,905; 32,359; then decreasing after sales to 911). Additionally, 3,500 shares are reported as indirectly owned by a trust for which the reporting person's spouse is trustee. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Ausiello on 08/15/2025.
Alnylam Pharmaceuticals (ALNY) reported a proposed sale under Rule 144 of 31,448 common shares valued at $13,635,538.00 based on the filing. The shares were acquired and are to be sold on 08/14/2025 through UBS Financial Services, Inc. via the exercise of stock options and paid in cash. The filing lists 131,079,015 shares outstanding for the class. The filer reports no shares sold in the past three months. The notice includes the signer’s representation that they are unaware of any undisclosed material adverse information about the issuer.